MOS
RVNC

MGO One Seven’s Revance Therapeutics, Inc. RVNC Stock Holding History

MGO One Seven’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$3K Hold
106
– – ﹤0.01% 1486
2017
Q4 		$4K Buy
+106
New +$3.04K ﹤0.01% 1390

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

MGO One Seven's RVNC Position: Q1 2018 in Review

MGO One Seven held its Revance Therapeutics, Inc. (RVNC) position steady in Q1 2018 at 106 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1486.

MGO One Seven first reported a position in RVNC in Q4 2017 and has held it in 2 quarters since. The position peaked at $4K in Q4 2017. 120 funds tracked by Wall St. Rank hold RVNC as of Q1 2018.

  • MGO One Seven held 106 shares of Revance Therapeutics, Inc. worth $3K as of Q1 2018.
  • MGO One Seven left its Revance Therapeutics, Inc. share count unchanged in Q1 2018.
  • Revance Therapeutics, Inc. made up ﹤0.01% of MGO One Seven's portfolio in Q1 2018, its #1486 holding.
  • MGO One Seven first reported a position in Revance Therapeutics, Inc. in Q4 2017 and has held it in 2 quarters since.
  • MGO One Seven's Revance Therapeutics, Inc. position peaked at $4K in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2018.

Based on MGO One Seven's 13F filing for Q1 2018, filed 15 May 2018.